Interventions for valvular disease Final results from the REPRISE I study: five-year clinical outcomes with the repositionable and fully retrievable LOTUS valve system Gooley R, Worthley S, Whitbourn R, Montarello J, Newcomb A, Allocco D, Meredith I December 7, 2018 | 10.4244/EIJ-D-18-00664
Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Meredith I, Verheye S, Dubois C, Dens J, Farah B, Carrié D, Walsh S, Oldroyd K, Varenne O, El-Jack S, Moreno R, Christen T, Allocco D April 20, 2018 | 10.4244/EIJ-D-17-00529
Interventions for valvular disease Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients Meredith I, Dumonteil N, Blackman D, Tchétché D, Walters D, Hildick-Smith D, Manoharan G, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Feldman T, Allocco D, Dawkins K September 20, 2017 | 10.4244/EIJ-D-16-01024
Interventions for valvular disease Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort Dumonteil N, Meredith I, Blackman D, Tchétché D, Hildick-Smith D, Spence M, Walters D, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Houle V, Allocco D, Dawkins K September 20, 2017 | 10.4244/EIJ-D-16-01025
Coronary interventions Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy Kereiakes D, Meredith I, Masotti M, Carrié D, Moreno R, Erglis A, Mehta S, Elhadad S, Berland J, Stein B, Airaksinen J, Jobe R, Reitman A, Janssens L, Christen T, Dawkins K, Windecker S March 20, 2017 | 10.4244/EIJ-D-16-00643
Coronary interventions Intravascular ultrasound guidance improves clinical outcomes during implantation of both first- and second-generation drug-eluting stents: a meta-analysis Nerlekar N, Cheshire C, Verma K, Ihdayhid A-R, McCormick L, Cameron J, Bennett M, Malaiapan Y, Meredith I, Brown A January 20, 2017 | 10.4244/EIJ-D-16-00769
Interventions for valvular disease Intrepid transcatheter mitral valve replacement system: technical and product description Meredith I, Bapat V, Morriss J, McLean M, Prendergast B September 18, 2016 | 10.4244/EIJV12SYA21
Coronary interventions Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program Abdel-Wahab M, Neumann F-J, Serruys P, Silber S, Leon M, Mauri L, Yeung A, Belardi J, Widimsky P, Meredith I, Saito S, Richardt G July 20, 2016 | 10.4244/EIJY15M07_07
Interventions for valvular disease The Accucinch transcatheter direct mitral valve annuloplasty system Gooley R, Meredith I September 17, 2015 | 10.4244/EIJV11SWA16
A Y-shaped bifurcation-dedicated stent for the treatment of de novo coronary bifurcation lesions: an IVUS analysis from the BRANCH trial Sakata K, Koo B, Waseda K, Nakatani D, Yock P, Whitbourn R, Worthley S, Ormiston J, Webster M, Wilkins G, Honda Y, Meredith I, Fitzgerald P March 20, 2015 | 10.4244/EIJY14M08_16
Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study Sievert H, Schofer J, Ormiston J, Hoppe U, Meredith I, Walters D, Azizi M, Diaz-Cartelle J, Cohen-Mazor M February 20, 2015 | 10.4244/EIJY14M12_01
Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study Meredith I, Worthley S, Whitbourn R, Antonis P, Montarello J, Newcomb A, Lockwood S, Haratani N, Allocco D, Dawkins K March 20, 2014 | 10.4244/EIJV9I11A216
Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months Serruys P, Onuma Y, Garcia-Garcia H, Muramatsu T, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert K, Rapoza R, Ormiston J March 20, 2014 | 10.4244/EIJV9I11A217
Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study Buysschaert I, Dubois C, Dens J, Ormiston J, Worthley S, McClean D, Ottervanger J, Meredith I, Uren N, Wijns W, Whitbourn R, Mehran R, Lansky A, Bichalska M, Meis S, Verheye S September 27, 2013 | 10.4244/EIJV9I5A93
Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Meredith I, Verheye S, Weissman N, Barragan P, Scott D, Valdés Chávarri M, West N, Kelbæk H, Whitbourn R, Walters D, Kubica J, Thuesen L, Masotti M, Banning A, Sjogren I, Stables R, Allocco D, Dawkins K July 26, 2013 | 10.4244/EIJV9I3A52
How should I treat a patient with symptomatic severe aortic stenosis and a 23 mm aortic annulus who is referred for transcatheter aortic valve replacement using the CoreValve prosthesis? Ko B, Antonis P, Meredith I, Tchétché D, Eggebrecht H, Zierer A, Doss M February 22, 2013 | 10.4244/EIJV8I10A186
Boston Scientific Lotus valve Meredith I, Hood K, Haratani N, Allocco D, Dawkins K September 30, 2012 | 10.4244/EIJV8SQA12
Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials Kereiakes D, Popma J, Cannon L, Kandzari D, Kimmelstiel C, Meredith I, Teirstein P, Verheye S, Allocco D, Dawkins K, Stone G June 27, 2012 | 10.4244/EIJV8I2A32
First-in-human experience with the Medtronic Bifurcation Stent System Meredith I, Worthley S, Whitbourn R, Webster M, Fitzgerald P, Ormiston J October 28, 2011 | 10.4244/EIJV7I6A108
PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses Meredith I, Whitbourn R, Scott D, El-Jack S, Zambahari R, Stone G, Teirstein P, Starzyk R, Allocco D, Dawkins K May 17, 2011 | 10.4244/EIJV7I1A15
New issue Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue (Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right)) December 6, 2019
Trials Book New update! Discover 17 new trials (The Trials book is supported by Biotronik) October 29, 2019
Editorial 2019 – A leap year for valvular heart disease (Course directors PCR London Valves 2019) November 15, 2019